Innate Pharma Total Liabilities

Innate Pharma (IPHA) currently reports a total liabilities of $75M as of June 2026. That compares with $88M in the prior-year period — down 14.3% year over year. Use the charts on this page to explore Innate Pharma's total liabilities history and peer comparisons.

Innate Pharma's total liabilities decreased from $88M to $75M — a 14.3% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Innate Pharma reported $75M in total liabilities as of June 2026. That compares with $88M in the prior-year period — down 14.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total liabilities of $75M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Innate Pharma, and consider following IPHA for alerts when major investors trade the stock.

Innate Pharma is classified in the Healthcare sector. On total liabilities, it currently shows $75M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing IPHA with unrelated industries.